tetano
Editor, Senior Moderator
J Infect
. 2024 Feb 9:S0163-4453(24)00036-7.
doi: 10.1016/j.jinf.2024.01.017. Online ahead of print. The clinical outcome of COVID-19 is strongly associated with microbiome dynamics in the upper respiratory tract
Linlin Xie[SUP] 1 [/SUP], Gengyan Luo[SUP] 2 [/SUP], Zhongzhou Yang[SUP] 2 [/SUP], Wei-Chen Wu[SUP] 2 [/SUP], Jintao Chen[SUP] 3 [/SUP], Yuting Ren[SUP] 3 [/SUP], Zhikun Zeng[SUP] 1 [/SUP], Guangming Ye[SUP] 1 [/SUP], Yunbao Pan[SUP] 1 [/SUP], Wen-Jing Zhao[SUP] 2 [/SUP], Yao-Qing Chen[SUP] 4 [/SUP], Wei Hou[SUP] 3 [/SUP], Yanni Sun[SUP] 5 [/SUP], Deying Guo[SUP] 2 [/SUP], Zifeng Yang[SUP] 6 [/SUP], Jun Li[SUP] 7 [/SUP], Edward C Holmes[SUP] 8 [/SUP], Yirong Li[SUP] 9 [/SUP], Liangjun Chen[SUP] 10 [/SUP], Mang Shi[SUP] 11 [/SUP]
Affiliations
Objectives: The respiratory tract is the portal of entry for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although a variety of respiratory pathogens other than SARS-CoV-2 have been associated with severe cases of COVID-19 disease, the dynamics of the upper respiratory microbiota during disease the course of disease, and how they impact disease manifestation, remain uncertain.
Methods: We collected 349 longitudinal upper respiratory samples from a cohort of 65 COVID-19 patients (cohort 1), 28 samples from 28 recovered COVID-19 patients (cohort 2), and 59 samples from 59 healthy controls (cohort 3). All COVID-19 patients originated from the earliest stage of the epidemic in Wuhan. Based on a modified clinical scale, the disease course was divided into five clinical disease phases (pseudotimes): "Healthy" (pseudotime 0), "Incremental" (pseudotime 1), "Critical" (pseudotime 2), "Complicated" (pseudotime 3), "Convalescent" (pseudotime 4), and "Long-term follow-up" (pseudotime 5). Using meta-transcriptomics, we investigated the features and dynamics of transcriptionally active microbes in the upper respiratory tract (URT) over the course of COVID-19 disease, as well as its association with disease progression and clinical outcomes.
Results: Our results revealed that the URT microbiome exhibits substantial heterogeneity during disease course. Two clusters of microbial communities characterized by low alpha diversity and enrichment for multiple pathogens or potential pathobionts (including Acinetobacter and Candida) were associated with disease progression and a worse clinical outcome. We also identified a series of microbial indicators that classified disease progression into more severe stages. Longitudinal analysis revealed that although the microbiome exhibited complex and changing patterns during COVID-19, a restoration of URT microbiomes from early dysbiosis towards more diverse status in later disease stages was observed in most patients. In addition, a group of potential pathobionts were strongly associated with the concentration of inflammatory indicators and mortality.
Conclusion: This study revealed strong links between URT microbiome dynamics and disease progression and clinical outcomes in COVID-19, implying that the treatment of severe disease should consider the full spectrum of microbial pathogens present.
Keywords: COVID-19; SARS-CoV-2; meta-transcriptomics; microbiome; upper respiratory tract.
. 2024 Feb 9:S0163-4453(24)00036-7.
doi: 10.1016/j.jinf.2024.01.017. Online ahead of print. The clinical outcome of COVID-19 is strongly associated with microbiome dynamics in the upper respiratory tract
Linlin Xie[SUP] 1 [/SUP], Gengyan Luo[SUP] 2 [/SUP], Zhongzhou Yang[SUP] 2 [/SUP], Wei-Chen Wu[SUP] 2 [/SUP], Jintao Chen[SUP] 3 [/SUP], Yuting Ren[SUP] 3 [/SUP], Zhikun Zeng[SUP] 1 [/SUP], Guangming Ye[SUP] 1 [/SUP], Yunbao Pan[SUP] 1 [/SUP], Wen-Jing Zhao[SUP] 2 [/SUP], Yao-Qing Chen[SUP] 4 [/SUP], Wei Hou[SUP] 3 [/SUP], Yanni Sun[SUP] 5 [/SUP], Deying Guo[SUP] 2 [/SUP], Zifeng Yang[SUP] 6 [/SUP], Jun Li[SUP] 7 [/SUP], Edward C Holmes[SUP] 8 [/SUP], Yirong Li[SUP] 9 [/SUP], Liangjun Chen[SUP] 10 [/SUP], Mang Shi[SUP] 11 [/SUP]
Affiliations
- PMID: 38342382
- DOI: 10.1016/j.jinf.2024.01.017
Objectives: The respiratory tract is the portal of entry for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although a variety of respiratory pathogens other than SARS-CoV-2 have been associated with severe cases of COVID-19 disease, the dynamics of the upper respiratory microbiota during disease the course of disease, and how they impact disease manifestation, remain uncertain.
Methods: We collected 349 longitudinal upper respiratory samples from a cohort of 65 COVID-19 patients (cohort 1), 28 samples from 28 recovered COVID-19 patients (cohort 2), and 59 samples from 59 healthy controls (cohort 3). All COVID-19 patients originated from the earliest stage of the epidemic in Wuhan. Based on a modified clinical scale, the disease course was divided into five clinical disease phases (pseudotimes): "Healthy" (pseudotime 0), "Incremental" (pseudotime 1), "Critical" (pseudotime 2), "Complicated" (pseudotime 3), "Convalescent" (pseudotime 4), and "Long-term follow-up" (pseudotime 5). Using meta-transcriptomics, we investigated the features and dynamics of transcriptionally active microbes in the upper respiratory tract (URT) over the course of COVID-19 disease, as well as its association with disease progression and clinical outcomes.
Results: Our results revealed that the URT microbiome exhibits substantial heterogeneity during disease course. Two clusters of microbial communities characterized by low alpha diversity and enrichment for multiple pathogens or potential pathobionts (including Acinetobacter and Candida) were associated with disease progression and a worse clinical outcome. We also identified a series of microbial indicators that classified disease progression into more severe stages. Longitudinal analysis revealed that although the microbiome exhibited complex and changing patterns during COVID-19, a restoration of URT microbiomes from early dysbiosis towards more diverse status in later disease stages was observed in most patients. In addition, a group of potential pathobionts were strongly associated with the concentration of inflammatory indicators and mortality.
Conclusion: This study revealed strong links between URT microbiome dynamics and disease progression and clinical outcomes in COVID-19, implying that the treatment of severe disease should consider the full spectrum of microbial pathogens present.
Keywords: COVID-19; SARS-CoV-2; meta-transcriptomics; microbiome; upper respiratory tract.